ReviewFrontiers in pharmacology2025
Shufeng Jiedu Capsules for treating wind-heat syndrome respiratory diseases: a systematic review and meta-analysis.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study systematically evaluates the efficacy and safety of Shufeng Jiedu Capsules in treating respiratory diseases with wind-heat syndrome patterns, providing clinical guidance and a reference for developing new "syndrome-dominating disease management" medications. Methods: A systematic search of CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, Embase, Web of Science, and trial registries identified randomized controlled trials (RCTs) assessing Shufeng Jiedu Capsules for wind-heat syndrome respiratory diseases (from inception to December 2024). Two researchers independently screened studies and extracted data using predefined criteria. Methodological quality was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 and Stata 18 were used for data analysis, and evidence quality was graded using the GRADE system. Results: Twenty-five RCTs involving 2681 patients were included, with 1339 in the experimental group and 1342 in the control group. The GRADE assessment indicated predominantly low or very low evidence certainty, mainly due to methodological flaws such as unclear allocation concealment, lack of blinding, and absence of protocol registration, which increased the risk of bias. Meta-analysis showed that Shufeng Jiedu Capsule combined with conventional biomedical therapy outperformed biomedical therapy alone. It improved the effective rate of traditional Chinese medicine syndromes (risk ratio [RR] = 1.17, 95% CI 1.10 to 1.24, Conclusion: Shufeng Jiedu Capsule combined with biomedicine may offer advantages in treating respiratory diseases with wind-heat syndrome. The adverse events were minor and controllable, and no serious adverse events were reported. However, the reliability of these findings is limited by low evidence certainty arising from methodological weaknesses in the included trials. High-quality, multicenter RCTs with rigorous methodology are essential to confirm these results. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251017879, identifier CRD420251017879.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.